Title: “Dawn of a New Era: Targeting the Neuromuscular Root Cause of OSA With Oral Pharmacotherapy”
Wednesday, December 10, 2025 at 1:00pm-2:00pm ET
Overview: Obstructive sleep apnea (OSA) is a serious, chronic disease characterized by sleep-related neuromuscular dysfunction and predisposing anatomic abnormalities, causing recurrent upper airway collapse during sleep. This results in chronic intermittent hypoxia, a key driver of OSA sequelae. Current therapies are efficacious in some patients, but additional options are needed for those who don’t benefit from or tolerate existing therapies. Join Dr. John Cronin, SVP Clinical Development at Apnimed, as he highlights the unmet needs of people living with OSA and provides a clinical update on AD109, an investigational oral tablet targeting the neuromuscular root cause of OSA.
Learning Objectives:
- Review the significant burden of OSA and the unmet treatment needs of people living with OSA.
- Educate on OSA pathophysiology and the link between pathophysiology, chronic intermittent hypoxia, and OSA sequelae.
- Explain how investigational AD109 targets sleep-related neuromuscular dysfunction of OSA, including what has been learned about its mechanism of action (MOA).
- Present AD109 clinical research data in adults with OSA.
Presenters: John Cronin, MD – SVP Clinical Development at Apnimed
Complimentary, Advanced Registration is Required.
